Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 222-048-3
CAS number: 3327-22-8
The key oral study, conducted in a manner similar to (the now
deleted) OECD 401 involved gavage administration of one of five doses of
a 60% solution of CHPTAC to male and female rats. An LD50 value of 3.2
mL/kg bw was reported (equivalent to 3688 mg/kg bw, or 2213 mg/kg bw for
The key dermal study, conducted according to OECD 402, involved
24-h occluded contact with the test material (65% aqueous CHPTAC). An
LD50 value in rats greater than 2348 mg/kg bw was derived for the test
material, that has been said to equate to 1526 mg/kg bw for 100% CHPTAC.
No suitable data are available for the inhalation route.
Table 1: Mortality
within 1 h of dosing; survivors recovered and there were no overt
signs of toxicity. No gross abnormalities were identified on
XRK 60) = 3.20 mL/kg bw.
3.68 g/kg bw (TS specific gravity 1.15)
to an LD50 for
100% CHPTAC of 2213 mg/kg bw/day
In an acute toxicity study, the toxic
potential of CHPTAC was tested dermally on male and female rats. A LD 50
value for 60% CHPTAC of 3.20 mL/kg bw was identified in male and female
rats. This would be equivalent to an LD50 for 100% CHPTAC of 2213 mg/kg
A limit test was conducted to assess
the dermal toxicity of the test substance (65% CHPTAC). Under the
experimental conditions the dermal LD50 value was found to be greater
than 2348 mg/kg which corresponds to 1526 mg/kg of pure CHPTAC.
The key oral study was chosen from 4 studies of reliability 2
(reliable with restrictions) as the most recent of those for which
sufficient data were available for review during entry to IUCLID5.
Findings from the remaining three studies supported those of the key
study. Where adequate data were available the LD50 values for pure
CHPTAC were in every case greater than 2000 mg/kg bw/day. For a further
two studies (reliability 4) an LD50 of >2000 mg/kg bw/day was also
given, apparently in relation to an aqueous solution of CHPTAC, giving a
conversion to an LD50 lower than 2000 mg/kg bw/day for the pure
substance. However, sufficient details were not available during entry
to IUCLID5 for this to be reliably ascertained.
The study selected by FIN to provide the LD50 used in risk
characterization (Kynoch et al., 1982/Dynamit Nobel, 1982) was not
available during entry to IUCLID5. The LD50 value identified in this
study is very similar to that of the key study.
The key dermal study was chosen from two very similar studies in
the rat. The findings of the supporting study confirm those of the key
Based on the available
data, classification via the oral route is not required (Regulation
(EC) No 1272/2008; Directive
The studies identified
do not indicate classification via the dermal route for the test
(EC) No. 1272/2008; Directive
67/548/EEC). However, conversion to account for the concentration of
CHPTAC in the test material means that the tested dose of pure CHPTAC
was slightly lower than the upper value (2000 mg/kg bw) above which
classification would not be required.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again